SCHEMBL31246225

SCHEMBL31246225

Fc1ccc2c(c1)COCC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
PDE3A Q14432 1/20 0.39
GRM2 Q14416 1/20 0.37
PIK3CD O00329 1/20 0.36
PTGS2 P35354 1/20 0.36
PARP1 P09874 2/20 0.34
PARP10 Q53GL7 1/20 0.34
NR3C2 P08235 1/20 0.34
KDM1A O60341 2/20 0.33
HTR2C P28335 2/20 0.33
HTR2A P28223 1/20 0.33
HTR1D P28221 1/20 0.32
HTR1B P28222 1/20 0.32
NOTUM Q6P988 1/20 0.32
KMT2A Q03164 1/20 0.32
HTR6 P50406 1/20 0.32
DPP9 Q86TI2 1/20 0.31
HTR2B P41595 1/20 0.31
NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9122886 1.00 CA1 (0.39) CA1CA2PDE3AGRM2PIK3CD
SCHEMBL19835515 0.92 CA1 (0.39) CA1CA2PDE3AGRM2PIK3CD
SCHEMBL20231255 0.88 CA1 (0.37) CA1CA2PDE3APTGS2PARP1
SCHEMBL29790845 0.75 PNMT (0.46) PIK3CDPARP1PARP10KDM1AHTR2C
SCHEMBL29989368 0.75 MAPT (0.40) CA1CA2PIK3CDKMT2AHTR6
SCHEMBL4523516 0.75 PNMT (0.46) PIK3CDPARP1PARP10KDM1AHTR2C
SCHEMBL19023151 0.75 DRD2 (0.43) CA2
SCHEMBL8237889 0.75 PIK3CD (0.36) PIK3CDPARP1PARP10NOTUMRAB9A
SCHEMBL9119279 0.75 PNMT (0.46) PIK3CDHTR6
SCHEMBL9125380 0.75 HTR2A (0.48) PIK3CDPARP1PARP10KDM1AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713320-A2 BCAT2 INHIBITORS Agios Pharmaceuticals, Inc. (US) 2026-03-25 EP disclosed
WO-2024238820-A2 BCAT2 INHIBITORS AGIOS PHARMACEUTICALS, INC. (US) 2024-11-21 WO disclosed